Search Results



Your search for The ASCO Post matches 6396 pages

Showing 1 - 50


lung cancer

IASLC 2017: Exercise Interventions in Advanced Lung Cancer Patients Led to Increased Functionality

Physical exercise and psychosocial interventions in patients with advanced-stage lung cancer improved functional capacity, which may be linked to quality-of-life benefits. Morten Quist, PT, PhD, MSc, of the University of Copenhagen, presented these findings at the International Association for the...

lung cancer

IASLC 2017: Community Engagement Interventions May Reduce Disparities in Lung Cancer Outcomes Among Minorities

Community-based interventions implemented in minority community sites resulted in changes in participants’ knowledge, attitudes, and beliefs about cancer, as well as perceived benefits and self-efficacy measures regarding lung cancer screening. Lovoria Williams, PhD, APRN-BC, FAANP, of...

lung cancer

IASLC 2017: Non–Small Cell Lung Cancer Survival Rates Higher Among Patients Treated at Academic Centers

As non–small cell lung cancer (NSCLC) survival rates have increased over time, new research sheds light on how NSCLC outcomes are significantly influenced by the type of treatment facility where patients undergo care. Bhagirathbhai Dholaria, MD, of the Moffitt Cancer Center, presented these...

lung cancer

IASLC 2017: Poziotinib Yields High Response Rates in Patients With NSCLC With EGFR Exon 20 Insertion

A targeted therapy studied at The University of Texas MD Anderson Cancer Center has produced high response rates among patients with metastatic non–small cell lung cancer (NSCLC) that carries a highly treatment-resistant mutation. Preliminary results were presented at the International...

lung cancer

IASLC 2017: First-Line Pembrolizumab Increases Overall Survival vs Chemotherapy in Metastatic NSCLC With High Levels of PD-L1

Updated overall survival findings from the phase III KEYNOTE-024 trial evaluating pembrolizumab (Keytruda) as a first-line monotherapy in patients with non–small cell lung cancer (NSCLC) whose tumors express high levels of programmed cell death ligand 1 (PD-L1) were presented at the...

lymphoma

FDA Approves CAR T-Cell Therapy to Treat Adults With Certain Types of Large B-Cell Lymphoma

On October 19, the U.S. Food and Drug Administration (FDA) approved axicabtagene ciloleucel (Yescarta), a cell-based gene therapy, to treat adult patients with certain types of large B-cell lymphoma who have not responded to or who have relapsed after at least two other kinds of treatment....

lung cancer

IASLC 2017: IASLC Releases New Atlas of EGFR Testing

The International Association for the Study of Lung Cancer (IASLC) released its Atlas of EGFR Testing in Lung Cancer at the IASLC 18th World Conference on Lung Cancer (WCLC) in Yokohama, Japan. The EGFR Atlas provides health-care professionals with information on EGFR testing processes and...

lung cancer

IASLC 2017: Treatment Based on BRCA1 Level Does Not Increase Survival of Stage II/III NSCLC Node-Positive Resected Patients

New research shows that treating stage II and III non–small cell lung cancer (NSCLC) node-positive resected patients with customized chemotherapy based on their specific BRCA1 expression levels, as opposed to providing the standard treatment, did not increase overall survival rates among...

lung cancer

IASLC 2017: Biopsy Specimen Found to Be Reliable for Evaluating DLL3 Expression in Small Cell Lung Cancer

Small cell lung cancer (SCLC) biopsy specimens were found to be reliable material for evaluating DLL3 expression, and high levels of DLL3 in SCLC are correlated with poor survival trends. Researchers from Guangdong General Hospital and Guangdong Academy of Medical Sciences in China presented...

Norman E. Sharpless, MD, Sworn in as Director of the National Cancer Institute

Norman E. “Ned” Sharpless, MD, took the oath of office late Tuesday, October 17, 2017, to become the 15th Director of the National Cancer Institute (NCI), part of the National Institutes of Health (NIH). He succeeds Harold E. Varmus, MD, who stepped down as Director in March 2015....

lung cancer

IASLC 2017: REVEL Trial Subgroup Analysis Further Clarifies Outcomes With Ramucirumab Plus Docetaxel in Advanced Non–Small Cell Lung Cancer

New subgroup analysis from the phase III REVEL trial of ramucirumab (Cyramza) in advanced non–small cell lung cancer (NSCLC) was presented at the International Association for the Study of Lung Cancer (IASLC) 18th World Conference on Lung Cancer in Yokohama, Japan. Specifically, these...

lung cancer

IASLC 2017: Research Confirms IASLC Characterization of Uncertain R Status With Prognosis Between R0 and R1

The findings of a recent study confirm the International Association for the Study of Lung Cancer (IASLC)’s proposed criteria for uncertain resection margin status, R(un), in residual tumor (R) classification. John Edwards, PhD, MBChB, of the University of Sheffield in the United Kingdom,...

lung cancer

IASLC 2017: Integration of Smoking Cessation With CT Lung Cancer Screenings

A study that integrated robust smoking cessation programs into an organized low-dose computed tomography (CT) lung cancer screening program found that the inclusion of both interventions has the potential to decrease mortality rates—while being relatively cost-effective. William Evans,...

kidney cancer

FDA Grants Priority Review for Cabozantinib in Previously Untreated Advanced Renal Cell Carcinoma

On October 16, the U.S. Food and Drug Administration (FDA) determined the supplemental New Drug Application (sNDA) for cabozantinib (Cabometyx) for patients with previously untreated advanced renal cell carcinoma (RCC) to be sufficiently complete to permit a substantive review. The FDA granted...

lung cancer

IASLC 2017: Race, Socioeconomic Factors Are Influential in NSCLC Survival Rates

New research found race and specific socioeconomic factors to have a significant influence on disparities in the survival rates of non–small cell lung cancer (NSCLC) patients. Yanyan Lou, MD, PhD, of the Mayo Clinic, presented these findings at the International Association for the Study of...

lung cancer

IASLC 2017: Lorlatinib in ALK-Positive and ROS1-Positive Advanced Non–Small Cell Lung Cancer

At the International Association for the Study of Lung Cancer (IASLC) 18th World Conference on Lung Cancer in Yokohama, Japan, Pfizer announced full results from the phase II clinical trial of the investigational, next-generation tyrosine kinase inhibitor lorlatinib. The agent exhibited clinically...

lung cancer

IASLC 2017: CheckMate-032: Nivolumab Alone or With Ipilimumab in Recurrent SCLC With High Tumor Mutation Burden

At the International Association for the Study of Lung Cancer (IASLC) 18th World Conference on Lung Cancer in Yokohama, Japan, Bristol-Myers Squibb announced data evaluating nivolumab (Opdivo) and nivolumab plus ipilimumab (Yervoy) in previously treated small cell lung cancer (SCLC) patients whose...

lung cancer

IASLC 2017: Brigatinib in ALK-Positive Non–Small Cell Lung Cancer

Data from the phase II ALTA clinical trial evaluating brigatinib (Alunbrig) in patients with locally advanced or metastatic anaplastic lymphoma kinase (ALK)-positive non–small cell lung cancer (NSCLC) who have disease progression on crizotinib were presented at the International...

lung cancer

IASLC 2017: Early Palliative Care Provides No Quality-of-Life Benefits for Patients With Recently Diagnosed Malignant Pleural Mesothelioma

Early specialist palliative care for patients that were recently diagnosed with malignant pleural mesothelioma does not impact quality-of-life measures, according to research presented by Fraser Brims, MBcHB, MRCP, MD, FRACP, of Curtin University in Australia, at the International Association...

lung cancer

IASLC 2017: Combination of Lurbinectedin and Doxorubicin in Relapsed Small Cell Lung Cancer

The final efficacy and safety data obtained from a phase I/II trial combining lurbinectedin (PM1183) with doxorubicin in relapsed small cell lung cancer were presented during a Research Perspectives oral session at the International Association for the Study of Lung Cancer (IASLC) 18th World...

health-care policy

Amended Health Insurance Rule Threatens Key Component of Standard Cancer Treatment

On October 12, ASCO President Bruce E. Johnson, MD, FASCO, issued the following statement: The Trump administration's move to expand the rights of employers to opt out of the requirement for contraceptive coverage would have unexpected and deleterious consequences for patients of childbearing age...

FDA Clears 7T Magnetic Resonance Imaging Device

On October 12, the U.S. Food and Drug Administration (FDA) cleared the first 7-Tesla (7T) magnetic resonance imaging (MRI) device, more than doubling the static magnetic field strength available for use in the United States. The Magnetom Terra is the first 7T MRI system cleared for clinical use in...

breast cancer

FDA Grants Priority Review for Abemaciclib as Initial Treatment of Advanced Breast Cancer

On October 12, Eli Lilly and Company announced that the U.S. Food and Drug Administration (FDA) granted Priority Review designation to its New Drug Application (NDA) for abemaciclib (Verzenio), a cyclin-dependent kinase (CDK) 4/6 inhibitor. MONARCH 3 The NDA was based upon the positive interim...

gynecologic cancers

sNDA Submitted for Rucaparib as Maintenace Treatment for Patients With Platinum-Sensitive Recurrent Ovarian Cancer

On October 9, Clovis Oncology announced that the company submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration for rucaparib (Rubraca) as maintenance treatment of patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer...

leukemia

Bruno C. Medeiros, MD, on AML: Targeted Treatment

Bruno C. Medeiros, MD, of Stanford Cancer Institute, discusses emerging novel agents and targeted molecular abnormalities in the management of acute myeloid leukemia.

lung cancer

Results From the Phase III JUNIPER Trial Evaluating Abemaciclib in KRAS-Mutated, Advanced NSCLC

On October 10, Eli Lilly and Company announced that its phase III JUNIPER study evaluating abemaciclib (Verzenio), a cyclin-dependent kinase (CDK) 4 and CDK6 inhibitor, as monotherapy in KRAS-mutated, advanced non–small lung cancer (NSCLC) did not meet its primary endpoint of overall...

gynecologic cancers

Role of the E7 Gene in High-Risk HPV

National Cancer Institute (NCI) researchers have found that for the most common high-risk type of human papillomavirus (HPV) to cause cervical cancer, an important viral gene may need to have a precise DNA sequence. The findings, published by Mirabello et al in Cell, contribute to a better...

lymphoma

Jane N. Winter, MD, on Follicular Lymphoma: Treatment Updates

Jane N. Winter, MD, of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, discusses the use of novel targeted therapies for newly diagnosed and relapsed/refractory follicular lymphoma.

lymphoma

Ranjana H. Advani, MD, on Hodgkin Lymphoma: New Management Options

Ranjana H. Advani, MD, of Stanford Cancer Institute, discusses the novel immunomodulatory agents used to manage patients with relapsed or refractory Hodgkin lymphoma.

lymphoma

Sharyn L. Kurtz, PA-C, MPAS, MA, on Managing Lymphoma Survivors

Sharyn L. Kurtz, PA-C, MPAS, MA, of Dana-Farber Cancer Institute, discusses the long-term side effects associated with curative treatments for Hodgkin lymphoma and non-Hodgkin lymphoma and how to develop an individualized follow-up schedule for survivors.

leukemia

David G. Maloney, MD, PhD, on ALL: New Therapeutic Agents

David G. Maloney, MD, PhD, of the Fred Hutchinson Cancer Research Center, reviews the clinical data and ongoing trials evaluating immunotherapy in the setting of relapsed or refractory acute lymphocytic leukemia and discusses major adverse events of treatment.

leukemia

William G. Wierda, MD, PhD, on CLL: How to Sequence Therapy

William G. Wierda, MD, PhD, of The University of Texas MD Anderson Cancer Center, discusses sequencing therapy in patients with relapsed/refractory CLL/SLL based on prior treatment and the presence of cytogenetic abnormalities.

hematologic malignancies

Ruben A. Mesa, MD, on Myeloproliferative Neoplasms: Managing PV and ET

Ruben A. Mesa, MD, of The University of Texas Health San Antonio Cancer Center, discusses the role of JAK2 inhibitors in treating polycythemia vera and essential thrombocythemia and how to develop individualized therapy based on risk stratification.

lung cancer

Osimertinib Granted Breakthrough Therapy Designation for First-Line Treatment of EGFR Mutation–Positive NSCLC

On October 9, AstraZeneca announced that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation for osimertinib (Tagrisso) for the first-line treatment of patients with metastatic epidermal growth factor receptor (EGFR) mutation–positive non–small cell lung ...

breast cancer

Relationship Between Targeted HER2 Therapy and Breast Reconstruction

Trastuzumab (Herceptin) therapy for breast cancers that express the HER2 protein does not increase the risk of complications at the surgical site in women who undergo immediate breast reconstruction after mastectomy, according to findings published by Shammas et al in the Journal of the American...

issues in oncology

Cancers Associated With Overweight and Obesity Make Up 40% of Cancers Diagnosed in the United States

Overweight and obesity are associated with increased risk of 13 types of cancer—and these cancers account for about 40% of all cancers diagnosed in the United States in 2014—according to the latest Vital Signs report by the Centers for Disease Control and Prevention (CDC). Overall, the...

lymphoma

Brentuximab Vedotin Granted FDA Breakthrough Therapy Designation in Front-Line Advanced Hodgkin Lymphoma

On October 2, Seattle Genetics, Inc, announced that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation to brentuximab vedotin (Adcetris) in combination with chemotherapy for the front-line treatment of patients with advanced classical Hodgkin lymphoma. The positive ...

issues in oncology
breast cancer

Treating Breast Cancer During Pregnancy Calls for Careful Timing of Therapies and Sensitive Discussions With Patients

Breast cancer during pregnancy is relatively uncommon; however, it poses a significant clinical challenge to the patient and her multidisciplinary care team. To shed light on this difficult issue, The ASCO Post spoke with Carey K. Anders, MD, a medical oncologist and researcher at the University...

Dana-Farber Opens New Facility for Integrative Therapies

DANA-FARBER CANCER INSTITUTE has announced the opening of the new Leonard P. Zakim Center for Integrative Therapies and Healthy Living.  Increasing data have indicated that integrative therapies can help alleviate the side effects of cancer therapy. The Zakim Center, as it is commonly referred to,...

AMA Awards Research Grants to Advance the Study of Women in Medicine

THE AMERICAN MEDICAL ASSOCIATION (AMA) recognizes influential female physician leaders as part of Women in Medicine Month each September. To showcase the accomplishments of these leaders, the AMA Women Physicians Section and the AMA Foundation recently announced the winners of the 2017 Joan F....

colorectal cancer

Immunotherapy for Metastatic Mismatch Repair–Deficient Colorectal Cancer: Game-Changer for Small Group of Patients

PATIENTS WITH DNA mismatch repair–deficient (dMMR) metastatic colorectal cancer display a high level of microsatellite instability (MSI-H)1 and demonstrate poor chemosensitivity and shorter overall survival than patients with mismatch repair–proficient (pMMR) metastatic metastatic colorectal...

hepatobiliary cancer

FDA Grants Accelerated Approval to Nivolumab for Hepatocellular Carcinoma Previously Treated With Sorafenib

ON SEPTEMBER 22, 2017, the U.S. Food and Drug Administration (FDA) granted accelerated approval to nivolumab (Opdivo) for the treatment of hepatocellular carcinoma in patients who have been previously treated with sorafenib (Nexavar).  CheckMate 040  APPROVAL WAS BASED on a 154-patient subgroup of ...

leukemia

Cord Blood Transplantation Proves Beneficial in High-Risk Patients With Leukemia

Studies show that only about one-third of patients with acute myeloid leukemia who have detectable amounts of cancer cells in their blood at the time of allogeneic hematopoietic cell transplantation will be alive 3 years later, compared with nearly three-quarters of those patients without minimal...

skin cancer

Blood-Based Biomarker: Predicting Efficacy of Immunotherapy in Patients With Melanoma

IN WHAT APPEARS TO BE the largest blood-based biomarker study of a checkpoint inhibitor, an RNA transcript–based gene classifier was able to predict for melanoma patients’ response to tremelimumab. The study was recently published in the Journal for ImmunoTherapy of Cancer.1  “Our study, in many...

gynecologic cancers

Expert Point of View: Sandro Pignata, MD

FORMAL DISCUSSANT of ARIEL3, Sandro Pignata, MD, of the IRCCS National Cancer Institute, “Fondazione G. Pascale,” Naples, Italy, said: “This is new evidence for maintenance therapy with rucaparib [Rubraca]. These results are extraordinary, particularly in the BRCA mutation patients, but also in...

lymphoma

FDA Approves Copanlisib for Relapsed Follicular Lymphoma

THE U.S. FOOD AND DRUG ADMINISTRATION (FDA) has granted accelerated approval to copanlisib (Aliqopa) for the treatment of adults with relapsed follicular lymphoma who have received at least two prior systemic therapies.  Copanlisib is a kinase inhibitor that works by blocking several enzymes that...

Journal of Clinical Oncology Literature Update

STAYING UP-TO-DATE in the fast-paced world of oncology literature is a daunting task at best. To assist with that task, The ASCO Post has assembled an assortment of studies recently published in the Journal of Clinical Oncology.  Sorafenib Dosing and Outcomes in Hepatocellular Cancer  IN A...

palliative care

Integrative Therapies in Palliative Care Project

Palliative care professionals are invited to participate in a unique project sponsored by the National Cancer Institute. Collinge and Associates, Inc, is seeking interdisciplinary professionals to help develop and evaluate a new online continuing education (CE/CME) course on the use of integrative...

hepatobiliary cancer

FDA Accepts sNDA for Lenvatinib for the Treatment of Hepatocellular Carcinoma

On September 26, Eisai Inc announced the U.S. Food and Drug Administration (FDA) has accepted for review a supplemental New Drug Application (sNDA) for lenvatinib  (Lenvima) for potential use in the first-line treatment of patients with hepatocellular carcinoma. “Patients with...

skin cancer

MSLT-II Completion Lymph Node Dissection Trial: Practice Changing but Not Likely Practice Abandoning

PROBABLY THE MOST IMPORTANT advance in the treatment of newly diagnosed primary melanoma has been the incorporation of sentinel lymph node biopsy as part of initial surgical management. The routine use of sentinel lymph node biopsy, often termed “sentinel lymphadenectomy,” in appropriately...

Advertisement



Advertisement


Advertisement